New inhaled drug aims to ease lung scarring and heart strain
NCT ID NCT06635850
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests an inhaled medication called mosliciguat in 135 people who have both lung scarring (interstitial lung disease) and high blood pressure in the lungs. Participants are randomly assigned to receive either the drug or a placebo for 16 weeks. The study measures changes in blood vessel resistance in the lungs and how far people can walk in six minutes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mosliciguat (inhaled)
What this could lead to
If successful, this could lead to a new inhaled treatment to improve blood flow and exercise ability in people with lung scarring and high blood pressure in the lungs.
What could go wrong
This is an early Phase 2 trial with only 135 people, so results may not confirm benefit. The drug may cause side effects or not work better than placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Arizona Pulmonary Specialists
Phoenix, Arizona, 85012, United States
-
Brown Medicine
East Providence, Rhode Island, 02915, United States
-
Duke University Health System - Duke Clinic
Durham, North Carolina, 27710, United States
-
Florida Lung, Asthma & Sleep Specialists/Clinical Research Specialists, LLC
Celebration, Florida, 34746, United States
-
Harbor-UCLA Medical Center - Torrance
Torrance, California, 90502, United States
-
Houston Methodist Lung Center
Houston, Texas, 77030, United States
-
Hoxworth Blood Center
Cincinnati, Ohio, 45267, United States
-
Lewis Katz School of Medicine
Philadelphia, Pennsylvania, 19140, United States
-
Medical University of South Carolina
Charleston, South Carolina, 29425, United States
-
Northwestern University
Chicago, Illinois, 60026, United States
-
Norton Pulmonary Specialists
Louisville, Kentucky, 40202, United States
-
PulmonIx
Greensboro, North Carolina, 27403, United States
-
Ronald Reagan UCLA Medical Center
Los Angeles, California, 90024, United States
-
Summit Health
Bend, Oregon, 97701, United States
-
University of California Davis School of Medicine
Sacramento, California, 95817, United States
-
University of Iowa Hospitals and Clinics
Iowa City, Iowa, 52242, United States
-
University of Kansas Medical Center
Kansas City, Kansas, 66160, United States
-
University of Utah Health
Salt Lake City, Utah, 84132-0001, United States